воскресенье, 25 декабря 2016 г.

Korean biopharmaceuticals to make inroad...

Korean biopharmaceuticals to make inroad...


A number of South Korean biopharmaceutical products will make their full-fledged debuts in the US next year, with the aim of taking a share of the world's largest market for pharmaceutical and health care goods. Leading the move is Celltrion, the developer of the world's first biosimilar drug referencing Johnson & Johnson's Remicade, which treats chronic inflammatory illnesses such as rheumatoid arthritis and Crohn's disease.



from Biotech News